Zanidatamab + Evorpacept
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-expressing Cancers
Conditions
HER2-expressing Cancers
Trial Timeline
Sep 15, 2021 → Sep 30, 2025
NCT ID
NCT05027139About Zanidatamab + Evorpacept
Zanidatamab + Evorpacept is a phase 1/2 stage product being developed by Jazz Pharmaceuticals for HER2-expressing Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT05027139. Target conditions include HER2-expressing Cancers.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05027139 | Phase 1/2 | Completed |
Competing Products
6 competing products in HER2-expressing Cancers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-4602 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| VIR-5818 + pembrolizumab | Merck | Phase 1/2 | 41 |
| ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine | Jazz Pharmaceuticals | Phase 2 | 49 |
| ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib | Jazz Pharmaceuticals | Phase 1 | 30 |
| ZW49 | Zymeworks | Phase 1 | 28 |